http://oxfordpharmascience.com/


Oxford Pharmascience is a drug development company that re-develops approved drugs to make them better, safer and easier to take.

Oxford Pharmascience is using its proprietary oral drug delivery technologies to develop improved formulations of non-steroidal anti-inflammatory drugs (NSAIDs) and statins for global markets.

The Company's risk-diversified pipeline of prescription and OTC medicines is focused on cardiovascular disease and pain relief indications. Since the products incorporate previously approved drugs, this reduces risk and results in a simplified drug development regulatory pathway allowing less expensive development programs and faster access to market.

The Company has also commercialized calcium/vitamin D chews that taste better and dissolve faster than currently available regular formats. These products are now marketed in the UK, Middle East and Brazil.

Oxford Pharmascience is located in the UK and is led by a highly experienced management team that directs and manages the outsourcing of its development; pre-clinical and clinical programs; and manufacturing to a trusted network of partners and suppliers.

The Company commercializes its portfolio of product opportunities through out-licensing to leading pharmaceutical companies worldwide. Currently the Company has partnerships with Aché Laboratories and Bayer.

Oxford Pharmascience (LON:OXP) was established by a team of entrepreneurs in 2008 and is a publicly listed company on London's Alternative Investment Market (AIM), with a strong blue chip investor base.

A three bagger at 3.81 :-))

Well done with this one dreamcatcher. I've just bought a few as I think the future is looking good.

up 11%

Thanks d4

http://www.barchart.com/opinions/stocks/OXP.LS&view=detailed

Doesn't get more positive than that - short term/medium term/long term -100% "buy".

Post 17 From Dec -

N+1 Singer sees Oxford Pharmascience (LON:OXP) as an appealing investment case thanks to its diversified technology platforms, strong IP protection and generic drugs dossier ownership.

The broker, which has a target price of 13.41p -

As of Feb 23, 2013, the investment analyst covering Oxford Pharmascience Group Plc advises that the company will outperform the market.


http://markets.ft.com/research/Markets/Tearsheets/Forecasts?s=OXP:LSE

Placing and Notice of General Meeting
RNS
RNS Number : 7271Y
Oxford Pharmascience Group PLC
27 February 2013



Oxford Pharmascience Group plc

("Oxford Pharmascience" or the "Company")



Placing and Notice of General Meeting



Oxford Pharmascience, the specialty pharmaceutical company that uses advanced pharmaceutic technologies to reposition medicines, announces that it has conditionally raised £5 million (before expenses) through the placing of 166,666,667 New Ordinary Shares at a placing price of 3p per Ordinary Share with discretionary funds managed by Invesco Asset Management Limited. N+1 Singer acted as broker to the Placing.

The placing of these 166,666,667 New Ordinary Shares (the "Placing") is conditional on the Company obtaining approval from Shareholders to their allotment at the General Meeting. The net proceeds of the Placing will be used by the Group to further accelerate the development of the Group's business as described in more detail below.

The circular relating to the Placing (the "Circular") will be posted to shareholders shortly. The Circular contains a notice convening a general meeting of the Company to approve certain matters relating to the Placing. The general meeting of the Company will be held at the offices of Fasken Martineau LLP, Third Floor, 17 Hanover Square, London W1S 1HU at 10.00 am on 19 March 2013.

The Circular will soon be available to view on the Company's website (www.oxfordpharmascience.com). Copies of the Circular will also be available from the registered offices of Oxford Pharmascience at Third Floor, 17 Hanover Square, London, W1S 1HU.

Nigel Theobald, CEO, commented:

"The Company has made strong progress over the past two years in developing and commercialising its innovative technology platforms and recently raised £2 million to strengthen its position for continuing this effort.

We are delighted to have Invesco on board as a major shareholder. This new placement will raise additional funds to allow us to accelerate our work on commercialising our technology platforms and to strengthen our IP position by developing our own dossiers for a range of NSAIDs which we will seek to license to major pharmaceutical companies"

Defined terms are appended to this announcement and have the same meaning as the Circular. The letter from the Chairman to be contained in the Circular is repeated below without material adjustment

Oxford Pharmascience gets heavyweight backing to speed up growth plans
7:55 am by Philip WhiterowOxford specialises in taste masking technologies that enable drugs to be taken more easily and with fewer side effects.

Oxford Pharmascience (LON:OXP) has brought on board a new major new shareholder though a fund raise to accelerate its growth plans.

Invesco Asset Management and its funds have taken up 166.7 mln new shares at 3p that will raise £5mln for the drug delivery group.

Oxford specialises in taste masking technologies that enable drugs to taken more easily and with fewer side effects.

Nigel Theobald, chief executive, said: “We are delighted to have Invesco on board as a major shareholder.

“This new placement will raise additional funds to allow us to accelerate our work on commercialising our technology platforms and to strengthen our IP position by developing our own dossiers for a range of NSAIDs [non steroidal anti-inflammatory drugs] which we will seek to license to major pharmaceutical companies."

In particular, Oxford said it wants to repeat the success it has enjoyed with its drug chew business, OXPchew, with taste masking technology platform OXPzero by first commercialising a product and then extending this to deals with other highly reputable pharmaceutical companies in the ibuprofen market.

Oxford also recently took up an option on from The School of Pharmacy, University College London to develop and commercialise a range of formulations of Simvastatin and Atorvastatin with reduced side effects.

The OXPtarget technology licensed from UCL will potentially allow the formulation of lower dose statins, with the equivalent lipid reduction effect of the current higher dose statin.

"The group's challenge is now to convert the OXPzero and OXPtarget technologies into real, exciting products that industry wants and to repeat the commercial success of OXPchew in the more attractive and higher value areas of NSAIDs and statins, Oxford said.

Shares have risen strongly since the start of the year. In November, Oxford raised £2mln through a placing at 1.3p.

With shares in Oxford Pharmascience (LON:OXP) steadily rising after a welter of good news from the drugs developer, heavyweight fund manager Invesco Asset Management decided it was time to get on board in a big way.

Invesco lobbed out £5mln to buy 166.7mln Oxford Pharma shares at 3p each, thereby joining a list of City institutions backing the company.

“This new placement will raise additional funds to allow us to accelerate our work on commercialising our technology platforms and to strengthen our IP [intellectual property] position by developing our own dossiers for a range of NSAIDs [non-steroidal anti-inflammatory drugs] which we will seek to license to major pharmaceutical companies," said Nigel Theobald, chief executive of Oxford Pharma.

Final Results

PERIOD HIGHLIGHTS

· Strong sales growth with Aché Laboratorios in Brazil

· Signing of first license with major pharmaceutical company, Bayer

· Signing of Heads of Terms with Hermes Pharma for OXP zero™ Ibuprofen direct to mouth granules

· Commencement of Safestat™ program for safer versions of Atorvastatin and Simvastatin

· Successful scale up of OXPzero™ ibuprofen

· £2m fund raising in November 2012

· Feasibility and option agreement signed with major pharmaceutical company for OXPzero™

· Successful in-vitro development of re-formulated Atorvastatin and Simvastatin




http://www.moneyam.com/action/news/showArticle?id=4558088

Oxford Pharmascience enjoys bounce from Brazil
11:00 am by John Harrington N+1 Singer has maintained its positive stance as it believes the group is positioning itself to capitalise on its pipeline of opportunities.


Eye-catching top line growth fed through to a sharp reduction in losses in 2012 at drugs developer Oxford Pharmascience (LON:OXP).

Results for the year were ahead of expectations, with revenue up 65% to £466,000 from £282,000 the year before, thanks in large part to strong sales in Brazil from one of the group’s OXPchew technology partners, Aché Laboratórios, and the generation of licensing and development income.

The loss before tax narrowed to £818,000 from £936,000 a year earlier. Loss per share contracted to 0.13p from a loss of 0.19p in 2011.

Market expectations were for revenue of £400,000, a loss before tax of £1mln and a loss per share of 0.20p.

Thanks to a tax rebate, Oxford Pharmascience’s post-tax loss was £783,000, versus a loss of £926,000 the year before.

The loss on operations reflects the company's investment during 2012 in developing and strengthening its platform technologies OXPzero and OXPtarget; the former is Oxford Pharma’s taste-masking technology which sets out to make redundant the old adage about the best medicine always tastes horrible, while OXPtarget is a drug delivery technology that aims to provide effective cholesterol-lowering medicine at lower dosage levels.

"We are continuing to show strong sales growth for our technology platform already in the market (OXPchew) and have strengthened our other technology platforms (OXPzero and OXPtarget) putting them in a strong position to secure attractive licensing deals,” said chief executive Nigel Theobald.

“We are very excited about the prospects for our platform technologies and are looking to continue our recent growth in the coming years," he added.

Shares in Oxford Pharmascience rose 0.5p to 3.35p in the first half hour of trading following the results.

The shares have been on a fantastic run over the last year, rising more than 150%, paving the way for a successful fund raising in late February, which saw heavyweight investor Invesco Asset Management pump £5mln into the group.

Those funds will enable the group to speed up its growth plans; essentially it will give the company the wherewithal to run test programmes in parallel rather than in series, Theobald explained to Proactive Investors last month.

“The group's challenge is now to convert the OXPzero and OXPtarget technologies into real, exciting products that industry wants and to repeat the commercial success of OXPchew in the more attractive and higher value areas of NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) and Statins,” said company chairman David Norwood.

House broker N+1 Singer has been bashing away at the calculator since the figures came out and has made some modest upward adjustments to its earnings forecasts for 2013 and 2014.

“Following the £5mln raise to progress the development of the group’s technology platforms, the statin offering in particular, we have increased the royalty rate we initially assigned to OXP target to 10% (from 3%) as we believe the group has the capability of progressing the development further on its own, and as a result, signing a more attractive commercial agreement. This has resulted in an intrinsic value of 6.8p per share,” N+1 Singer said.

The broker has maintained its positive stance as it believes the group is positioning itself to capitalise on its pipeline of opportunities.

“The change in focus to the higher value pharmaceutical market in 2011 is proving to have been a pivotal decision and one, in our view, that has the potential to reap significant benefits,” the broker said

Seems to be stirring into life again today, news in the pipeline?

Another 5% today doodlebug

Good news just out dreamcatcher;

Oxford Pharmascience Group PLC
08 May 2013
Oxford Pharmascience Group plc
("Oxford Pharmascience" or "the Company")
Oxford Pharmascience announces successful study indicating reduced gastric irritation for OXPzero(TM) ibuprofen and initiates Safer NSAIDs programme
Oxford Pharmascience, the specialty pharmaceutical company that uses advanced pharmaceutic technologies to make medicines better, safer and easier to take, today announces that it has established animal proof of concept and is starting a programme to develop safer NSAIDs applying its proprietary OXPzero(TM) technology.
There is a strong pharmacological rationale for reduced gastric irritation for NSAIDs delivered via the OXPzero(TM) technology and the company has demonstrated via a pharmacological study in mice that its OXPZero Ibuprofen material significantly reduces the irritation and ulcerating damage of ibuprofen. This is an exciting development for the company's technology as this shows that OXPzero(TM) has a much wider application in the field of NSAIDs to produce safer NSAID drugs.
NSAIDs are one of the most widely used classes of drugs, with more than 30 million users worldwide consuming NSAIDs each day and annual sales of $12 billion. In spite of this commercial success, chronic use of NSAIDs causes well documented gastrointestinal (GI) side effects. These side effects include ulcers and bleeding and lead to significant morbidity and mortality in many patients.
Nigel Theobald, Chief Executive Officer of Oxford Pharmascience commented,
"We will now use this breakthrough in our research to begin a programme to develop a range of safer NSAIDs with much lower gastric irritation. OXPzero has already been developed for ibuprofen and will now be incorporated into high dose tablet formats of 400mg and above.
New versions of other popular NSAIDs such as diclofenac, naproxen and aspirin will also be developed.
By re-formulating existing NSAIDs which are bio-equivalent we avoid the need for expensive and lengthy new drug development to combat the gastric problem. This is at the core of all we do and further demonstration that by re-developing existing drugs to make them safer or easier to take, we can access the high value returns associated with new drugs but for a fraction of the cost and with a much quicker timescale."

Oxford Pharmascience surges on ibuprofen test results
By John Harrington May 08 2013, 11:42am Oxford's technology could allow for higher dosages of ibuprofen without the stomach irritation that often accompanies chronic consumption.Oxford's technology could allow for higher dosages of ibuprofen without the stomach irritation that often accompanies chronic consumption.

Tests on laboratory mice have given a big boost to Oxford Pharmacience’s (LON:OXP) OXPzero technology.

As anyone who has read the small print on the back of a packet of Ibuprofen will know, one of the major drawbacks to taking the medicine, and other non-steroidal anti-inflammatory drugs (NSAIDs), is the possibility of gastric irritation (GI).

A recent pharmacological study in mice has demonstrated that OXPZero Ibuprofen material reduces the irritation and ulcerating damage of ibuprofen.

The tests indicate that Oxford’s OXPzero technology may have a bigger future in the lucrative NSAIDs market worldwide than previously thought.

NSAIDs are one of the most widely used classes of drugs, with more than 30 million users worldwide consuming NSAIDs each day and annual sales of US$12 billion, but the market could be bigger still if a company can crack the problem of GI side effects. These side effects include ulcers and bleeding and lead to significant morbidity and mortality in many patients.

Nigel Theobald, chief executive officer of Oxford Pharmascience commented: "We will now use this breakthrough in our research to begin a programme to develop a range of safer NSAIDs with much lower gastric irritation. OXPzero has already been developed for ibuprofen and will now be incorporated into high dose tablet formats of 400mg and above.”

New versions of other popular NSAIDs such as diclofenac, naproxen and aspirin will also be developed.

One of the advantages of Oxford Pharma’s focus on out of patent or nearly out of patent drugs is that the bulk of the drug development and regulatory hoop-jumping has been done, which means Oxford’s development programmes are comparatively inexpensive and swift. As such, a full range of OXPzero safer NSAIDs could be on the market as early as 2016.

Shares in Oxford Pharmascience shot up 6.2% to 4.01p on the news.

Oxford Pharmascience to develop range of safer anti-inflammatory drugs
By John Harrington May 08 2013, 3:41pm NSAIDs are one of the most widely used classes of drugs, with more than 30 million users worldwide consuming NSAIDs each dayNSAIDs are one of the most widely used classes of drugs, with more than 30 million users worldwide consuming NSAIDs each day

Wednesday’s announcement of a successful study indicating OXPzero ibuprofen could reduce stomach irritation side-effects is a step forward in an archetypal Oxford Pharmascience (LON:OXP) low-risk/high-reward programme.

While the study was only conducted on mice, the breakthrough could be significant. The genetic and biological characteristics of mice are close to those of humans, which is one of the reasons they are so widely used in medical research.

The pharmacological study showed that Oxford’s OXPzero Ibuprofen material reduces the irritation and ulcerating damage of ibuprofen.

Ibuprofen, along with the likes of aspirin and paracetamol, is one of the main “go-to” pain killers available over the counter today. It has long been proved to be effective in easing pain and swelling, and is a member of a group of medicines called non-steroidal anti-inflammatory drugs, or NSAIDs for short.

According to the NHS, ibuprofen can cause a number of side effects, including: nausea, vomiting, diarrhoea, indigestion and abdominal pain.

Less common side effects include: headache, inflammation of the stomach (gastritis), duodenal or gastric ulcers.

The results from the tests on mice, if repeated in humans, could see the irritation and ulcerating damage of ibuprofen significantly reduced.

For Oxford Pharmascience this is potentially big news.

“It could increase the number of people able to take ibuprofen, and it could enable existing users to increase the frequency of the dosage,” Oxford’s chief executive officer Nigel Theobald told Proactive Investors.

That could increase the size of the ibuprofen market, estimated to be worth US$12bn in annual sales globally, but more importantly, it could give the UK company a shot at a significant slice of this enormous market.

After all, given a choice between an ibuprofen tablet that is going to upset your tummy and possibly even cause ulcers and internal bleeding, and a product that minimises the prospect of unpleasant side effects, which are you going to choose?

OXPzero has already been used to develop ibuprofen products, including chewable tablets and suspensions, without any irritation or burn in the throat. With products created using Oxford’s technology, Mary Poppins would not need the spoonful of sugar to help the medicine go down.

The latest breakthrough is something different, though.

“This extends the OXPzero proposition beyond taste masking into the area of gastrointestinal side effects,” Theobald stressed.

Theobald said the company would now press ahead with a programme to develop a range of safer NSAIDs that are less likely to cause gastric irritation.

Following a successful fund raising in February, Oxford has the firepower to instigate this programme without having to divert resources from its other programmes, such as the highly promising cholesterol-lowering statin development.

“We’ll be able to develop in parallel, rather than in series, “ Theobald explained.

“It’s a classic example of what we do. It’s what we call re-engineering of everyday drugs that have issues. There’s nothing wrong with ibuprofen, but it has some issues, such as gastrointestinal irritation, so we want to address those.”

By focusing on drugs that have already passed all the regulatory hurdles, Oxford saves itself an enormous amount of time, energy and money. Instead of say, an uncertain journey to market that could take several years, as is the case with a new drug discovery, re-engineering an existing drug offers a safer, shorter journey to market.

“By re-developing existing drugs to make them safer or easier to take, we can access the high value returns associated with new drugs but for a fraction of the cost and with a much quicker timescale," Theobald said.

If all goes well, Oxford should have a full range of safer NSAIDs available to the market by 2016, thereby opening up the huge NSAIDs market to its reformulation technology. By full range, the company means the likes of diclofenac, naproxen and our old friend aspirin.

By any measure, that's news that is easy to stomach.

Oxford Pharmascience, up 3.97%, was wanted after it announced the results of a study on mice which showed that its OXPzero Ibuprofen material reduces the irritation and ulcerating damage of ibuprofen.

If the results are repeated in humans, then that will be great news for pain sufferers who cannot abide the side effects of taking non-steroidal anti-inflammatory drugs (NSAIDs); these include ulcers and bleeding, and in extreme cases can lead to significant poor health or even death.

The NSAIDs market is an absolutely massive one, with around US$12bn a year spent on this class of drugs. If Oxford can crack the problem of gastrointestinal side effects then the market will be even bigger, and the UK company would be set to grab a significant slice of it.

Oxford Pharmascience shares advance further on ibuprofen data
By Ian Lyall May 09 2013, 12:52pm At 1pm, the shares were changing hands for 4 pence each and their value has increased 150% in the past year. At 1pm, the shares were changing hands for 4 pence each and their value has increased 150% in the past year.

Shares in Oxford Pharmascience (LON:OXP) advanced a further 2% on Thursday and built on Wednesday’s gains as the market continued to digest data on its safer iteration of a top selling painkiller.

OXP’s study indicated its OXPzero Ibuprofen could reduce stomach irritation side-effects.

While the research was only conducted on mice, the breakthrough could be significant.

The genetic and biological characteristics of mice are close to those of humans, which is one of the reasons they are so widely used in medical research.

The pharmacological assessment showed that Oxford’s OXPzero Ibuprofen material reduces the irritation and ulcerating damage of ibuprofen.

Broker N+1 Singer said the results were a “very significant and important” step for the group and added that that OXP product had “remarkable potential”.

“There are over 30 million people consuming NASIDs (non-steroidal anti-inflammatory drugs) every day, generating around US$12 billion in annual sales, providing a very attractive opportunity to the group,” said analyst Sheena Berry.

“We note the impressive share price performance over the last seven months and believe this momentum should continue as the company progresses its programmes through development.”

At 1pm, the shares were changing hands for 4 pence each and their value has increased 150% in the past year.